🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 6 of 55

  1. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  2. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Non-small Cell Stage IV

    phase 2 small molecule active

    1 trial

  3. Almonertinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. Almonertinib

    The First People's Hospital of Lianyungang

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Almonertinib 110 MG

    Chinese University of Hong Kong

    Rare Tumor

    phase 2 small molecule active

    1 trial

  7. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  8. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  9. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  10. Amcenestrant

    Sanofi Pasteur

    Breast Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  11. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  13. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  14. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  15. Anlotinib

    The First People's Hospital of Lianyungang

    Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Anlotinib and Sintilimab injection

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  17. Anlotinib combined Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Anlotinib plus Pemetrexed

    Henan Provincial People's Hospital

    Non-squamous Cell Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Anlotinib+ Liposomal Doxorubicin

    The First People's Hospital of Lianyungang

    Sarcoma

    phase 2 small molecule active

    1 trial

  20. Anrotinib plus Tirelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  21. Anti-BCMA-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  22. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

  23. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  24. Anti-CD20-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  25. Anti-CD30-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  26. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  27. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial

  28. Anti-PD-1 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. Anvumetostat

    Amgen

    Advanced MTAP-null Solid Tumors

    phase 2 small molecule active

    1 trial

  30. Apalutamide

    Janssen Cilag International NV

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

  31. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  32. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  33. Apatinib

    Hospital Authority, Hong Kong

    Soft Tissue Sarcoma, Adult, Stage II

    phase 2 small molecule active

    1 trial

  34. Apatinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  35. Apatinib

    The First People's Hospital of Lianyungang

    Intrahepatic Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  36. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Esophageal Squamous Carcinoma

    phase 2 small molecule active

    1 trial

  37. Apatinib

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial

  38. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  39. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  40. Apatinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  41. Apatinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  43. Apatinib Combined With SHR-1210 Injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  44. Apatinib Mesylate +SHR-1210

    Chinese University of Hong Kong

    Hepatocellular Carcinoma

    phase 2 other active

    1 trial

  45. Apatinib mesylate tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  46. Apatinib mesylate tablets

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  47. Apatinib+ SHR-1210（Camrelizumab）

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  48. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.